Rekik A. Muluye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rekik A. Muluye has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abebaye Aragaw Leminie
Department of Medical Physiology, Addis Ababa University, Addis Ababa, Ethiopia
1 shared publication - Abiy Abebe
Traditional and Modern Medicine Directorates, Armauer Hansen Research Institute, Ethiopia, Ethiopia
1 shared publication - Beza Tasew Degefu
Non-communicable Disease Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia
1 shared publication - Getahun Tsegaye Dibaba
School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
1 shared publication Huantian Cui
Tianjin University of Traditional Chinese Medicine Tianjin, China
1 shared publicationLi Wang
Tianjin Second People’s Hospital Tianjin, China
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by MDPI AG in Preprints.org
Evaluation of the Glucose and Lipid-Lowering Effects of Methanol Extract of Mangifera Indica Leaf in Streptozotocin Induced Diabetic Mice
Background: Diabetic animals show increased plasma glucose, cholesterol, triglycerides, and low-density lipoprotein levels, along with decreased body weight and glycogen in the liver and muscles. While effective diabetic treatments are still being investigated, plants and herbs have historically contributed to treatment of ailments. The current study explores an alternative, complementary and potential treatment for diabetes. In ethno-medicine, various parts of Mangifera indica are used to treat diabetes mellitus. Methods: The present study aims at investigating antidiabetic, hypolipidemic, and histopathological analysis of Mangifera indica leaf methanolic extract (MIME) in streptozotocin-induced diabetic mice by administering different oral doses (200,400 and 600 mg/kg body weight). After induction of diabetes, the animals are assigned into six groups (one control group and five treatment groups). The treatment groups are treated by different dose of extract, and glibenclamide, and their blood glucose levels were measured. The BGL recording is done using blood glucose test strips OneTouch glucometer on weekly intervals for five weeks. Hematology and other parameters such as liver, renal and total lipid profiles were determined in normal and streptozotocin-induced diabetic mice after oral administration of the extract for 28 days. Post-treatment histopathological changes in the diabetic mice organs, like the pancreas, liver, and kidney, were assessed at the end of treatments. Results: Daily oral administration of MIME (200,400 and 600 mg/kg body weight) and glibenclamide (6 mg/kg) showed significant effects on blood glucose level (PConclusions: Mageferin indica possess anti-diabetic property in diabetic mice. It improves body weight, liver profile, renal profile and lipid profiles. It has a favorable effect in inhibiting diabetic-induced damage of islets of Langerhans in the pancreas.
- 1 December 2025
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of the Glucose and Lipid-Lowering Effects of Methanol Extract of Mangifera Indica Leaf in Streptozotocin Induced Diabetic Mice
Background: Diabetic animals show increased plasma glucose, cholesterol, triglycerides, and low-density lipoprotein levels, along with decreased body weight and glycogen in the liver and muscles. While effective diabetic treatments are still being investigated, plants and herbs have historically contributed to treatment of ailments. The current study explores an alternative, complementary and potential treatment for diabetes. In ethno-medicine, various parts of Mangifera indica are used to treat diabetes mellitus. Methods: The present study aims at investigating antidiabetic, hypolipidemic, and histopathological analysis of Mangifera indica leaf methanolic extract (MIME) in streptozotocin-induced diabetic mice by administering different oral doses (200,400 and 600 mg/kg body weight). After induction of diabetes, the animals are assigned into six groups (one control group and five treatment groups). The treatment groups are treated by different dose of extract, and glibenclamide, and their blood glucose levels were measured. The BGL recording is done using blood glucose test strips OneTouch glucometer on weekly intervals for five weeks. Hematology and other parameters such as liver, renal and total lipid profiles were determined in normal and streptozotocin-induced diabetic mice after oral administration of the extract for 28 days. Post-treatment histopathological changes in the diabetic mice organs, like the pancreas, liver, and kidney, were assessed at the end of treatments. Results: Daily oral administration of MIME (200,400 and 600 mg/kg body weight) and glibenclamide (6 mg/kg) showed significant effects on blood glucose level (PConclusions: Mageferin indica possess anti-diabetic property in diabetic mice. It improves body weight, liver profile, renal profile and lipid profiles. It has a favorable effect in inhibiting diabetic-induced damage of islets of Langerhans in the pancreas.
- Open Access
- 27 September 2016
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 328
Placenta Peptide Can Protect Mitochondrial Dysfunction through Inhibiting ROS and TNF-α Generation, by Maintaining Mitochondrial Dynamic Network and by Increasing IL-6 Level during Chronic Fatigue
Background: Level of fatigue is related to the metabolic energy available to tissues and cells, mainly through mitochondrial respiration, as well fatigue is the most common symptom of poorly functioning mitochondria. Hence, dysfunction of these organelles may be the cause of the fatigue seen in CF. Placenta has been used for treatment of fatigue and various disease, moreover peptides has known protect mitochondrial viability, and alleviate fatigue. These properties of placenta and peptides may link with its effect on mitochondria; therefore, it is highly important to investigate the effectiveness of placenta peptide on fatigue and mitochondrial dysfunction. Methods: - After administration of sheep placenta peptide (SPP) for one month, mice’s were forced to swim till exhaustion for 90 minute to induce chronic fatigue. Electron microscopic examination of skeletal muscle mitochondrial structure, tissue MDA, mitochondrial SOD and serum inflammatory cytokines level were investigated in order to determine the potential effect of sheep placenta peptide (SPP) on mitochondria during CF. Rat skeletal muscle (L6 cell) were also treated with different concentration of SPP to determine the effect of SPP on cell viability using MTT assay. Results: - Our finding revealed that forced swimming induced fatigue model can cause mitochondrial damage through ROS mediated lipid peroxidation and TNF-α elevation. Whereas SPP protected fatigue induced mitochondrial dysfunction through preventing ROS and TNF-α generation, by maintaining mitochondrial dynamic network and by increasing serum IL-6 level. Conclusion: - SPP can protect damage in mitochondrial components which will allow proper functioning of mitochondria that will in turn inhibit progression of chronic fatigue. Therefore, SPP may represent a novel therapeutic advantage for preventing mitochondrial dysfunction in patients with chronic fatigue.
- 27 September 2016
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 328
Open AccessPlacenta Peptide Can Protect Mitochondrial Dysfunction through Inhibiting ROS and TNF-α Generation, by Maintaining Mitochondrial Dynamic Network and by Increasing IL-6 Level during Chronic Fatigue
Background: Level of fatigue is related to the metabolic energy available to tissues and cells, mainly through mitochondrial respiration, as well fatigue is the most common symptom of poorly functioning mitochondria. Hence, dysfunction of these organelles may be the cause of the fatigue seen in CF. Placenta has been used for treatment of fatigue and various disease, moreover peptides has known protect mitochondrial viability, and alleviate fatigue. These properties of placenta and peptides may link with its effect on mitochondria; therefore, it is highly important to investigate the effectiveness of placenta peptide on fatigue and mitochondrial dysfunction. Methods: - After administration of sheep placenta peptide (SPP) for one month, mice’s were forced to swim till exhaustion for 90 minute to induce chronic fatigue. Electron microscopic examination of skeletal muscle mitochondrial structure, tissue MDA, mitochondrial SOD and serum inflammatory cytokines level were investigated in order to determine the potential effect of sheep placenta peptide (SPP) on mitochondria during CF. Rat skeletal muscle (L6 cell) were also treated with different concentration of SPP to determine the effect of SPP on cell viability using MTT assay. Results: - Our finding revealed that forced swimming induced fatigue model can cause mitochondrial damage through ROS mediated lipid peroxidation and TNF-α elevation. Whereas SPP protected fatigue induced mitochondrial dysfunction through preventing ROS and TNF-α generation, by maintaining mitochondrial dynamic network and by increasing serum IL-6 level. Conclusion: - SPP can protect damage in mitochondrial components which will allow proper functioning of mitochondria that will in turn inhibit progression of chronic fatigue. Therefore, SPP may represent a novel therapeutic advantage for preventing mitochondrial dysfunction in patients with chronic fatigue.